Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.
S K MahilM YatesS M LanganZ Z N YiuT TsakokN DandKayleigh J MasonH McAteerF MeynellB CokerA VincentD UrmstonA VestyJ KellyC LancelotL MoorheadHerve BachelezI N BruceFrancesca CaponC R ContrerasA P CopeC De La CruzPaola Di MeglioPaolo GisondiK HyrichD JullienJ LambertH Marzo-OrtegaI McInnesL NaldiS NortonLluis PuigR SenguptaP SpulsTiago TorresR B WarrenH WaweruJ WeinmanC E M GriffithsJ N BarkerM A BrownJ B GallowayC H Smithnull nullPublished in: The British journal of dermatology (2021)
Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk-mitigation strategies and may help inform updated public health guidelines as the pandemic continues.